Outstanding Early Career Scholar Program


Outstanding Early Career Scholar Program

The Department of Medicine, through this program, invests in the career development of each Scholar, and is not limited to a specific research project or scholarly activity. Early Career Scholars will be expected to commit 75% of their effort to scholarly activities. The Outstanding Early Career Scholar Program will provide each Scholar with $75,000 annually for up to four years. These funds will only be used to support the career development, research, or innovative work of the Scholar. These funds cannot be used to support or supplement the Scholar’s salary. Progress will be evaluated every year.  

Department of Medicine Announces 2020 Outstanding Early Career Scholars


Sridharan Raghavan, MD, PhD is an Assistant Professor of Medicine in the Division of Hospital Medicine and the Division of Biomedical Informatics and Personalized Medicine, and he is an attending physician in the Section of Hospital Medicine at the Rocky Mountain Regional VA Medical Center. His research focuses on precision medicine applied to type 2 diabetes—that is, how diabetes prevention and treatment can be individualized to maximize patient benefit and minimize harm. To that end, he uses large clinical databases and genetic data to better characterize the heterogeneity of type 2 diabetes patients in a way that can inform tailoring interventions and optimizing outcomes.

Dr. Raghavan will use this award to investigate how recent genetic advances involving diabetes and related cardiometabolic traits can be made clinically applicable using data from clinical biobanks and national genetic consortia. In addition to funding from the OECSP, he is the recipient of a VA Career Development Award.

Frank_Scott_headshotFrank I. Scott, MD, MSCE is an Assistant Professor of Medicine in the Division of Gastroenterology and Hepatology. His research interests include maximizing the risk-benefit balance of biologic and immunosuppressive therapies, optimizing medication delivery and biologic positioning, and exploring novel pharmacoepidemiologic associations in inflammatory bowel disease (IBD) and other gastrointestinal disorders.

Dr. Scott will use this award to support research identifying modifiable factors that delay biologic initiation and increase the risks of adverse outcomes including prolonged steroid exposure, hospitalization, or surgery in IBD. He will also use this support to assess the impact of peri-operative exposure to HMG-coA reductase inhibitors on post-operative fibrosis and adhesion formation in patients with Crohn’s disease who require intestinal resection.

Dates for Funding Cycles:

​Application Deadline

Application Form - click here

​January 1, 2021
​Award Start Date​July 1, 2021